Serum <i>Wisteria floribunda</i> agglutinin‐positive Mac‐2‐binding protein levels and liver fibrosis: A meta‐analysis

Ito, Kiyoaki; Murotani, Kenta; Nakade, Yukiomi; Inoue, Tadahisa; Nakao, Haruhisa; Sumida, Yoshio; Kamada, Y.; Yoneda, Masashi

doi:10.1111/jgh.13802

Cited by 47 publications

(41 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…M2BP has been identified as one of the major glycoproteins secreted from injured hepatocytes. WFA + -M2BP is a glycan structure isoform of M2BP and can be measured with a rapid, simple glycan-based immunoassay to quantify liver fibrosis in different chronic liver diseases [ 11 , 17 , 18 ]. The first study to assess the performance of WFA + -M2BP in predicting disease severity in NAFLD was done by Abe et al and included 289 Japanese patients with biopsy-proven disease.…”

Section: Discussionmentioning

confidence: 99%

“…Several recent studies have shown that Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA + -M2BP) is a promising biomarker in predicting the severity of liver fibrosis in different chronic liver diseases [ 11 ]. Mac-2 (galectin-3) binding protein (M2BP) is a glycoprotein that is almost undetectable in normal liver but becomes easily detected in patients with hepatocyte injury as liver fibrosis progresses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

et al. 2018

View full text Add to dashboard Cite

ObjectiveThe race for finding effective treatments for nonalcoholic fatty liver disease (NAFLD) has been slowed down by the high screen-failure rate for including patients in trials due to the lack of a noninvasive biomarker that can identify patients with significant disease. Recently, Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+ -M2BP) has shown promise in predicting liver fibrosis. The aims of this study were to evaluate the utility of WFA+ -M2BP as a biomarker to sub-classify patients with NAFLD according to their disease severity and to assess its correlation with histologic features of NAFLD.MethodsPatients undergoing biopsy for clinical suspicion of NAFLD and healthy controls were included. Patients with NAFLD were classified into: NAFL, early NASH (F0-F1), fibrotic NASH (F2-F3), and NASH cirrhosis (F4). Levels of WFA+ -M2BP in sera was measured by a HISCL™ M2BPGi™ assay kit using an automated immunoanalyzer (HISCL™-800; Sysmex, Kobe, Japan). Analysis of covariance was used to assess difference in WFA+ -M2BP between the groups and Spearman’s correlation coefficients were used to assess correlation with histological features.ResultsOur cohort consisted of 20 healthy controls and 198 patients with biopsy-proven NAFLD divided as follows: 52 with NAFL, 62 with early NASH, 52 with fibrotic NASH, and 32 with NASH cirrhosis. WFA+ -M2BP level was found to be significantly increased in the fibrotic NASH and NASH cirrhosis groups compared to healthy controls and those with early NAFLD after adjusting for age, gender and BMI. Furthermore, patients with NASH cirrhosis had significantly higher WFA+ -M2BP levels (2.4[1.5, 4.2] C.O.I (Cut-off Index)) than those with fibrotic NASH (1.2[0.79, 1.9]), p < 0.001. WFA+ -M2BP level had moderate correlation with inflammation, ballooning and NAFLD activity score and strong correlation with fibrosis stage. Additionally, ROC curve analysis demonstrated that WFA+ -M2BP accurately differentiated F2-4 from F0-F1.ConclusionIn a large cohort of patients with the full spectrum of NAFLD, WFA+ -M2BP levels predicted the presence of advanced disease and correlated strongly with fibrosis stage.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Measurement of the serum WFA + ‐M2BP level is now covered by the health insurance system in Japan. A recent meta‐analysis showed that the serum level of WFA + ‐M2BP is useful for detecting advanced fibrosis or as well as for predicting HCC development in patients with chronic liver disease, including hepatitis B virus, hepatitis C virus, and NAFLD …”

Section: Discussionmentioning

confidence: 99%

“…In the past, numerous noninvasive panels of tests have been developed for the staging of liver fibrosis, including a combination of clinica and routine laboratory parameters, as well as specialized tests involving direct markers of fibrosis. Recently, Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein (WFA + ‐M2BP) was discovered as a novel serum glycomarker for marker of liver fibrosis from glycoproteomic biomarker screening studies …”

Section: Introductionmentioning

confidence: 99%

Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease

Ogawa

Honda

Kessoku

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Fibrosis markers also have been extensively examined, including hyaluronic acid, type IV collagen 7S, procollagen III peptide and Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+ -M2BP). A recent meta-analysis showed that measurement of the serum level of WFA+ -M2BP, which is now covered by the health insurance system in Japan, is useful for detecting severe fibrosis or predicting HCC development in patients with chronic liver disease [ 28 ]. WFA+ -M2BP is also of clinical use for assessing liver fibrosis in patients with NAFLD [ 29 , 30 ].…”

Section: Biomarkers and Scoring Systemsmentioning

confidence: 99%

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods

et al. 2017

Self Cite

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic liver injury in many countries. The incidence of NAFLD is rising rapidly in both adults and children, because of the currently ongoing epidemics of obesity and type 2 diabetes. Notably, histological liver fibrosis is recognized as the main predictive factor for the overall long-term outcome of NAFLD, including cardiovascular disease and liver-related mortality. Thus, staging of liver fibrosis is essential in determining the prognosis and optimal treatment for patients with NAFLD and in guiding surveillance for the development of hepatocellular carcinoma (HCC). Whereas liver biopsy remains the gold standard for staging liver fibrosis, it is impossible to enforce liver biopsy in all patients with NAFLD. Noninvasive biological markers, scoring systems and noninvasive modalities are increasingly being developed and investigated to evaluate fibrosis stage of NAFLD patients. This review will highlight recent studies on the diagnosis and staging of NAFLD based on invasive (liver biopsy) or noninvasive (biomarker, scoring systems, US-based elastography and MR elastography) methods.

show abstract

Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein levels and liver fibrosis: A meta‐analysis

Abstract: These results suggest that serum WFA -M2BP is a reliable predictor for liver fibrosis staging and a good substitute for liver biopsy. It is also useful for predicting both hepatocellular carcinoma development and overall survival.

Cited by 47 publications

References 42 publications

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods

Contact Info

Product

Resources

About